2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies

Program: Oral Abstract Session
Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

113 Prospective comparison of once-weekly and twice-weekly Bortezomib in vrd induction and consolidation in TE-NDMM from the remnant trial

Lars Henrik Dahl Hamnvik, MD, Anne-Marie Rasmussen, PhD2, Anna Lysén, PhD3, Pegah Abdollahi, PhD4, Einar Haukås, MD5, Magnus Moksnes, MD6, Anette Eilertsen, MD, PhD7, Galina Tsykunova, MD8, Birgitte Eiken, MD9, Nils Morten Leknes, MD10, Jürgen Rolke, MD11, Vidar Stavseth, MD12, Eivind Samstad, MD, PhD13, Randi Fykse Hallstensen, MD14, Damian Szatkowski, MD, PhD15, Liv Osnes, MD, PhD16, Mona Høysæter Fenstad, MD, PhD17, Anna Parente-Ribes, MD, PhD18, Barbora Jacobsen, MD19, Ariane Aasbø Hansen20, Anita Smith Nilsen21, Tobias S. Slørdahl, MD, PhD22, Fredrik Schjesvold, MD,PhD23, Frida Bugge Askeland, MD, PhD24
1 Drammen Hospital, Drammen, Buskerud, Norway, Oslo Myeloma Center, Oslo University Hospital, Oslo, Oslo, Norway, University of Oslo, Oslo, Norway
2 Oslo Myeloma Center, Oslo University Hospital, Oslo, Oslo, Norway
3 Oslo Myeloma Center, Oslo University Hospital, Oslo, Oslo, Norway
4 Oslo Myeloma Center, Oslo University Hospital, Oslo, Oslo, Norway
5 Stavanger Universitessjukehus, Stavanger, Norway
6 Vestfold Hospital Trust, Tønsberg, Norway
7 Akershus University Hospital, Lørenskog, Akershus, Norway
8 Haukeland Unviersity Hospital, Bergen, Norway
9 Østfold Hospital Kalnes, Grålum, Norway
10 University Hospital of North Norway, Tromsø, Norway
11 Sørlandet Hospital, Kristiansand, Norway
12 Levanger Hospital, Levanger, Norway
13 Ålesund Hospital, Ålesund, Norway, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, University Of Science and Technology, Ålesund, Norway
14 Nordland Hospital, Bodø, Norway
15 Førde Central Hospital, Førde, Norway
16 Oslo University Hospital, Oslo, Norway
17 St Olavs Hospital, Trondheim, Norway
18 Universitetet i Oslo, Oslo, Oslo, Norway
19 St Olavs Hospital, Trondheim, Norway
20 Oslo Myeloma Center, Oslo University Hospital, Oslo, Oslo, Norway
21 Oslo Myeloma Center, Oslo University Hospital, Oslo, Oslo, Norway
22 Norwegian University of Science and Technology (NTNU), Trondheim, Norway, St Olavs Hospital, Trondheim, Norway
23 Oslo Myeloma Center, Oslo University Hospital, Oslo, Oslo, Norway
24 Oslo Myeloma Center, Oslo University Hospital, Oslo, Oslo, Norway

Background: The proteasome inhibitor bortezomib is a cornerstone of first-line treatment for transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM). It is a potent anti-myeloma drug and has few significant side effects other than peripheral neuropathy (PN), its main dose-limiting toxicity. The optimal dosing regimen for bortezomib that balances response against the incidence and severity of PN is unknown. Results from the REMNANT trial provide important information on how to optimize bortezomib dosing in TE-NDMM.     

Methods: REMNANT is an ongoing academic, multicenter, open-label phase 2/3 study in TE-NDMM patients aged 18-75 with broad inclusion criteria.

All patients received 21-day cycles of bortezomib, lenalidomide and dexamethasone (VRd), four induction and four consolidation cycles, separated by single or tandem autologous stem cell transplant. Bortezomib was administered subcutaneously at 1.3 mg/m² on days 1, 4, 8, and 11 in the first 200 patients (twice-weekly group), and on days 1 and 8 in the last 181 patients (once-weekly group). Lenalidomide was given orally at 25 mg/day on days 1-14. Dexamethasone was given orally at 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12.

This sub-analysis of the REMNANT study evaluates the incidence and severity of PN after consolidation in TE-NDMM treated with twice-weekly or once-weekly bortezomib. PN was graded according to Common Terminology Criteria for Adverse Events Version 5.0. The incidence and grade of PN, response rates and progression-free survival (PFS) are compared between the two different treatment groups.

Results: 382 patients were included in the first part of the REMNANT study between August 2020 and September 2024. One patient was excluded from the analysis because of withdrawal before receiving any treatment. The overall baseline characteristics were similar between the two treatment groups. The incidence of PN of any grade was markedly lower in the once-weekly group with 40.3% compared to 75.5% in the twice-weekly group (p-value <0.001). Grade 1 PN was numerically lower in the once-weekly group with 26.5% compared to 34.5% in the twice-weekly group (p-value 0.159). Grade 2 and 3 PN were also less frequent in the once-weekly group, with 12.7% vs 35.5% grade 2 (p-value <0.001) and 1.1% vs 5.5% grade 3 (p-value 0.022) in the once-weekly and twice-weekly group, respectively. No grade 4 PN was reported. Other adverse events were comparable between the groups except for more grade 2 or higher thrombocytopenia (9.5% vs 2.2%) and ocular events (15% vs 3.9%) in the twice-weekly group. The median dose intensity of bortezomib was 75% in the twice-weekly group and 100% in the once-weekly group. The median cumulative dose was 28.6 mg/m² and 20.8 mg/m² in the twice-weekly and once-weekly group, respectively (p-value <0.001). In the twice-weekly group, 154/200 (77%) patients required bortezomib dose reductions, 106 (69%) due to PN, compared with 46/181 (25%) in the once-weekly group, 25 (54%) due to PN.

At the end of consolidation, achievement of minimal residual disease (MRD)-negative complete response (CR), the primary endpoint of the trial, was similar; 34% in the twice-weekly group and 31.5% in the once-weekly group. Overall response rates were also similar; 96 % versus 92.3 %, as were rates of CR or better; 44% and 42.5%, in the twice-weekly and once-weekly group respectively. However, the rate of very good partial response (VGPR) or better was higher in the twice-weekly group than in the once-weekly group: 90.5% vs 80.7% (p-value 0.009).

As of June 2026, median follow-up was 50.5 months in the twice-weekly group and 28 months in the once-weekly group, reflecting the later inclusion period of the once-weekly group. PFS at 12 and 24 months were similar between groups; 89.9% and 80.5% in the twice-weekly group and 88.5% and 78.2% in the once-weekly group (p-value 0.67 and 0.60).

Conclusion: Once-weekly compared to twice-weekly bortezomib in VRd induction and consolidation for TE-NDMM up to 75 years of age resulted in a significantly reduced incidence and severity of PN. Despite a lower median cumulative bortezomib dose in the once-weekly group, overall response rates, MRD-negative CR rates, and PFS were similar between the two treatment groups. This supports the use of once-weekly bortezomib in VRd regimens for TE-NDMM. These data could change the registrational paradigm of twice-weekly treatment.

Lars Henrik Dahl Hamnvik, MD: No relevant conflicts of interest to declare.